Comparing treatments for macular degeneration: findings and impact @CochraneCollab
Comparing treatments for macular degeneration: findings and impact  @CochraneCollab
Uploaded January 2015 | Updated November 2026, 20 hours ago
This video tells the story of a Cochrane review which compared two treatments for macular degeneration - bevacizumab (brand name Avastin®) and intravitreal ranibizumab (brand name Lucentis®). It represents an important step forward in the knowledge about differences in systemic harms between these two drugs. Find out more about why, along with one story of how this Cochrane review has already made a difference.

Read the review here: cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-abs-0003
Comparing treatments for macular degeneration: findings and impactCochrane: 30 years of evidenceThe early years of The Cochrane CollaborationHow to leverage social media as an early career researcherWhat is the Cochrane Early Career Professionals Network? Mission, vision and opportunitiesAbout CochraneCan a free meal influence what your doctor prescribes?Can xylitol used in products help prevent tooth decay?Pathways in Cochrane CrowdTracking your progress in Cochrane CrowdCochrane’s Future of Evidence Synthesis Programme: A transformationDiscover Cochrane: how the organization works and ways to get involved
Cochrane |

Comparing treatments for macular degeneration: findings and impact

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER